medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2011, Number 4

<< Back Next >>

Arch Neurocien 2011; 16 (4)

Usefulnes of vestibular enoked myogemic potenial cervical (PMEVc) in total control of ablation with gentamcin vestibular Ménière’s disease with unilateral vertigo unresponsive to medial treatment

Hinojosa-González R, Morales-Orta C, Vales-Hidalgo O, Delgado-Hernández RD, Burgos-Centeno J

Language: Spanish
References: 34
Page: 223-227
PDF size: 265.87 Kb.


ABSTRACT

The utility of cervical vestibular evoked myogenic potentials (cVEMPs) of Ménière´s disease has been demonstrated by both, early diagnosis and the monitoring of the efficacy of the intratympanic Gentamicin therapy used for chemical vestibular ablation in patients whose in spite of the conventional medication, persist with incapacitating dizziness, preferring this treatment over other options of more invasive ones. Nevertheless the inherent risk of ablative gentamicin therapy is the hearing loss even when it is used on a weekly administration basis or very low doses of aminoglukoside. There are also other schemes of complete vestibular ablation and partial vestibular ablation, for which, in both cases, the main objective is the satisfactory control of dizziness in short and long term. We presented the case of a man with definitive unilateral Ménière disease, incapacitating dizziness and useful hearing function without response to the medical treatment, in which a complete chemical vestibular ablation with intratympanic gentamicin was realized, achieving an adequate control of vestibular symptoms and preservation of the hearing function through the six years follow up. The scheme used in our hospital is a complete chemical vestibular ablation, equivalent to a vestibular neurectomy when is monitored by means of cVEMPs, where recurrence is rare, the weekly basis administration in low doses offers a lower risk of hypoacusia.


REFERENCES

  1. Ferber-Viart C, Dubreuil C, Duclaux R. Vestibular evoked myogenic potentials in humans: a review. Acta Otolaryngol 1999;119:6-15.

  2. Bacsi AM, Watson SR, Colebatch JG. Galvanic and acoustic vestibular stimulation activate different populations of vestibular afferents. Clin Neurophysiol 2003;114(2):359-65.

  3. Murofushi T, Halmagyi GM, Yavor RA, Colebatch JG. Absent vestibular evoked myogenic potentials in vestibular neurolabyrinthitis: an indication of inferior vestibular nerve involvement? Arch Otolaryngol Head Neck Surg 1996;122:845-8.

  4. Matsuzaki M, Murofushi T. Vestibular evoked myogenic potentials in patients with idiopathic bilateral vestibulopathy: report of three cases. J Otorhinolaryngol Relat Spec 2001;63:349-52.

  5. Roditi Rachel E, Eppsteiner Robert W, Sauter Todd B. Cervical vestibular evoked myogenic potentials (cVEMPs) in patients with superior canal dehiscence syndrome (SCDS). Otolaryn Head Neck Surgery 2009;141,24-8.

  6. Wu J, Wang J, Xie J, Han L, Gao L. Clinical characterization of audiometrics and vestibular evoked myogenic potentials in patients with large vestibular aqueduct syndrome. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2010;24(1):25-7.

  7. Murofushi T, Matsuaki M, Mizuno M. Vestibular evoked myogenic potentials in patients with acoustic neuroma. Arch Otolaryngol Head Neck Surg 1998; 124:509–12.

  8. De Waele C, Huy PTB, Diard JP, Freyss G, Vidal PP. Saccular dysfunction in Ménière’s disease. Am J Otol 1999;20:223–32.

  9. De Waele C. Saccular dysfuntion in Ménière’s patients. A vestibularevoked myogenic potencial study. Ann NY Acad Sci 1999;871:392-7.

  10. Pappas DG, Pappas DG. Vestibular nerve section: long-term followup. Laryngoscope 1997;107:3-9.

  11. Yazdi AK, Rutka J. Results of labyrinthectomy in the treatment of Mèniére´s disease and delayed endolymphatic hydrops. J Otolaryngol 1996;25:26-31.

  12. Gacek RR, Gacek MR. Comparison of labyrinthectomy and vestibular neurectomy in the control of vertigo. Laryngoscope 1996; 106:225-30.

  13. Cohen-Kerem R, Kisilevsky V, Einarson TR, Kozer E, Koren G, Rutka JA. Intratympanic gentamicin for Mèniére´s disease: a metaanalysis. Laryngoscope 2004;114:2085Y91.

  14. Stefano AD, Dispenza F, Donato GD, Caruso A, Taibah A, SannaM. Intratympanic gentamicin: a 1-day protocol treatment for unilateral Mèniére´s disease. Am J Otolaryngol Head Neck Med Surg 2007;28:289-93.

  15. Sala T. Transtympanic gentamicin in the treatment of Mèniére´s disease. Auris Nasus Larynx 1997; 24: 239-46.

  16. Bauer PW, MacDonald CB, Cox LC. Intratympanic gentamicin therapy for vertigo in nonserviceable ears. Am J Otolaryngol 2001;22: 11-5.

  17. Casani A, Nuti D, Franceschini SS, Gaudini E, Dallan I. Transtympanic gentamicin and fibrin tissue adhesive for treatment of unilateral Mèniére´s disease: effects on vestibular function. Otolaryngol Head Neck Surg 2005; 133:929-35.

  18. Toth AA, Parnes LS. Intratympanic gentamicin therapy for Ménière’s disease: preliminary comparison of two regimens. J Otolaryngol 1995;24:340-4.

  19. Driscoll CL, Kasperbauer JL, Facer GW, Harner SG, Beatty CW. Low-dose intratympanic gentamicin and the treatment of Ménière’s disease: preliminary results. Laryngoscope 1997; 107: 83-9.

  20. Hirsch BE, Kamerer DBHL. Intratympanic gentamicin therapy for Ménière’s disease. Am J Otol 1997; 18: 44-51.

  21. Minor LB. Intratympanic gentamicin for control of vertigo in Ménière’s disease: vestibular signs that specify completion of therapy. Am J Otol 1999;20:209-19.

  22. Boleas-Aguirre MS, Sánchez-Ferrandiz N, Guillén-Grima F, Perez N. Long term disability of class A patients with Mèniére´s disease after treatment with intratympanic gentamicin. Laryngoscope 2007; 117(8):1474-81.

  23. Rauch SD, Oas JG. Intratympanic gentamicin for treatment of intractable Ménière’s disease: a preliminary report. Laryngoscope 1997;107;49-55.

  24. Chia SH, Gamst AC, Anderson JP, Harris JP. Intratympanic gentamicin therapy for Ménière’s disease: a meta-analysis. Otol Neurotol 2004;25(4):544-52.

  25. Committee on Hearing and Equilibrium. Guidelines for the diagnosis and evaluation of Mèniére´s disease. Otolaryngol Head Neck Sur 1995;113:181-5.

  26. Young Y. Assessing the stage of Mèniére´s disease using vestibular evoked myogenic potencials. Arch Otolaryngol Head Neck Surg 2003; 129:815-8.

  27. Young Y, Wu CC, Wu CH. Augmentation of vestibular evoked myogenic potencials: an indication for distended saccular hydrops. Laryngoscope 2002a;112:509-12.

  28. Young Y, Huang TW, Cheng PW. Vestibular evoked myogenic potencials in delayed endolynphatic hydrops. Laryngoscope 2002b; 112:1623-6.

  29. Murofushi T, Matsuzaki M, Takegoshi H. Glycerol affects vestibular evoked myogenic potentials in Mèniére’s disease. Auris Nasus Larynx 2001a;28:205-8.

  30. Seo T, Node M, Yukimasa A, Sakagami M. Furosemide Loading Vestibular Evoked Myogenic Potential for Unilateral Ménière’s Disease. Otol & Neurotol 2003;24:283-8.

  31. Chong Lee Lim, Clouston P, Sheean G, Yiannikas C. The influence of voluntary EMG activity and click intensity on the vestibular click evoked myogenic potential 1995;18:1210-3.

  32. Kimura RS, Lee KS, Nye CL, Trehey JA. Effects of systemic and lateral semicircular canal administration of aminoglycosides on normal and hydropic inner ears. Acta Otolaryngol 1991;111: 1021-30.

  33. Okuda T, Sugahara K, Shimogori H, Yamashita H. Inner ear changes with intracochlear gentamicin administration in guinea pigs. Laryngoscope 2004;114:694-7.

  34. Harner SG, Driscoll CL, Facer GW, Beatty CW, McDonald TJ. Longterm follow-up of transtympanic gentamicin for Menière’s syndrome. Otol Neurotol 2001;22:210-4.




2020     |     www.medigraphic.com